BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2492837)

  • 1. Increased tissue-plasminogen activator (t-PA) levels in patients under oral anticoagulant therapy.
    Grulich-Henn J; Loechelt K; Speiser W; Müller-Berghaus G
    Blut; 1989 Jan; 58(1):39-43. PubMed ID: 2492837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
    Nguyen G; Horellou MH; Kruithof EK; Conard J; Samama MM
    Blood; 1988 Aug; 72(2):601-5. PubMed ID: 3135860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
    Auwerx J; Bouillon R; Collen D; Geboers J
    Arteriosclerosis; 1988; 8(1):68-72. PubMed ID: 2449156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
    Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
    Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion.
    Cugno M; Uziel L; Fabrizi I; Bottasso B; Maggiolini F; Agostoni A
    Thromb Res; 1989 Dec; 56(5):625-34. PubMed ID: 2516662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolytic response to venous occlusion for 10 and 20 minutes in healthy subjects and in patients with deep vein thrombosis.
    Petäjä J
    Thromb Res; 1989 Oct; 56(2):251-63. PubMed ID: 2515609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
    Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
    Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
    Stegnar M; Mavri A
    Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
    Francis RB; McGehee WG; Feinstein DI
    Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis].
    Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B
    Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
    Lucore CL; Fujii S; Sobel BE
    Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
    Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
    Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
    Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
    J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
    Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
    Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.
    Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK
    Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between smoking and fibrinolytic system with special reference to t-PA and PA inhibitor.
    Hashimoto Y; Kobayashi A; Yamazaki N; Takada Y; Takada A
    Thromb Res; 1988 Aug; 51(3):303-11. PubMed ID: 3140409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
    Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
    Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased fibrinolytic activity after surgery induced by low dose heparin.
    Arnesen H; Engebretsen LF; Ugland OM; Seljeflot I; Kierulf P
    Thromb Res; 1987 Mar; 45(5):553-9. PubMed ID: 3109060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved fibrinolytic capacity after withdrawal of steroid immunosuppression in renal transplant recipients.
    Sartori MT; Patrassi GM; Rigotti P; Marchini F; Fioretti M; Spiezia L; Girolami A
    Transplantation; 2000 May; 69(10):2116-21. PubMed ID: 10852608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.